Clinical Trials Browser

Active not recruiting × OTHER × cemiplimab × Clear all

NCT04315701 2026-06-01

A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

Phase 2 Active not recruiting

Skin Neoplasms

NCT06855212 2026-05-20

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05574101 2026-05-15

A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer

Phase 2 Active not recruiting

Carcinoma, Squamous Cell, Skin Neoplasms

NCT05694871 2026-05-11

Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

Phase 2 Active not recruiting

Liposarcoma

NCT05961709 2026-05-04

The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

Phase 2 Active not recruiting

Gastrointestinal

Colonic Neoplasms

NCT05704634 2026-04-15

A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.

Phase 1 Active not recruiting

Lung Neoplasms

NCT05553834 2026-04-13

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

Skin Neoplasms

NCT05401786 2026-03-12

RAD-IO

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03565783 2026-02-25

Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery

Phase 2 Active not recruiting

DermatologicHead & Neck

Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck

NCT04862650 2026-02-10

Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

Phase EARLY_PHASE1 Active not recruiting

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT04243616 2025-09-05

CemiHALT

Phase 2 Active not recruiting

Invasive Breast Cancer

NCT04706715 2025-05-31

LAG3 PET Imaging in Advanced Solid Tumors

Phase 1/2 Active not recruiting

Neoplasm Metastasis, Neoplasms

NCT03951831 2025-04-25

REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer

Phase 2 Active not recruiting

Neoplasms, Prostatic Neoplasms

NCT05878288 2024-11-21

DISCERN

Phase 2 Active not recruiting

Neoplasms

NCT04679480 2024-07-30

Anti-PD1-antibody and Pulsed HHI for Advanced BCC

Phase 2 Active not recruiting

Carcinoma, Basal Cell